The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Source: News Medical, https://www.news-medical.net/